Read by QxMD icon Read

Bisphosphonates IV

James S Goodwin, Jie Zhou, Yong-Fang Kuo, Jacques Baillargeon
OBJECTIVE: To compare the risk of jaw osteonecrosis after intravenous (IV) bisphosphonate administered to patients with cancer vs patients without cancer. PATIENTS AND METHODS: We conducted a retrospective cohort study of a 5% national sample of Medicare patients administered IV bisphosphonate from January 1, 2008, through December 31, 2013, for cancer vs noncancer indications. Probable jaw osteonecrosis was estimated with an algorithm including diagnoses, surgical procedures, and imaging studies...
November 19, 2016: Mayo Clinic Proceedings
Kirollos Gendi, David Hennessy, John Heiner
BACKGROUND: In the United States, over 1,650,000 new cases of cancer are being diagnosed yearly with almost 50 % of them being the top five bone-seeking cancers. Since cancer risk increases with age, this suggests that orthopedic oncology services may be a strain on the Medicare system. The femur is the most common site of long bone metastases. Prophylactic fixation techniques prevent pathologic fractures, reduce morbidities, and enhance the quality of life of patients with femoral metastases...
2016: SpringerPlus
Ho Duy Binh, Katre Maasalu, Vu Chi Dung, Can T Bich Ngoc, Ton That Hung, Tran V Nam, Le N Thanh Nhan, Ele Prans, Ene Reimann, Lidiia Zhytnik, Sulev Kõks, Aare Märtson
PURPOSE: Osteogenesis imperfecta (OI) has not been studied in a Vietnamese population before. The aim of this study was to systematically collect epidemiological information, investigate clinical features and create a clinical database of OI patients in Vietnam for future research and treatment strategy development. METHOD: Participants underwent clinical and physical examinations; also medical records were reviewed. Genealogical information was collected and family members' phenotypical manifestations recorded...
November 2, 2016: International Orthopaedics
Leonid S Grossman, Amber L Price, Eric T Rush, Jennifer L Goodwin, Maegen J Wallace, Paul W Esposito
BACKGROUND: To report a single-center surgical experience treating humeral deformity and fractures in children with osteogenesis imperfecta (OI) using the Fassier-Duval (FD) intramedullary elongating rods. METHODS: A retrospective review was conducted between December 2005 and July 2013 of all OI patients who underwent FD rodding with a minimum of 1-year follow-up. All patients were also being concurrently treated with bisphosphonates. RESULTS: Eighteen patients underwent internal fixation on a total of 35 humeri: 7 males and 11 females with an average age of 49 months...
September 22, 2016: Journal of Pediatric Orthopedics
Pietro Persiani, Filippo Maria Ranaldi, Lorena Martini, Anna Zambrano, Mauro Celli, Patrizia D'Eufemia, Ciro Villani
BACKGROUND: Osteogenesis imperfecta (OI) is a rare congenital genetic osteodystrophy, which has a prevalence of 1:20,000. OI is caused by the mutation of the COL1A1/COL1A2 genes, leading to a deficit of quality and/or quantity in the synthesis of procollagen-α type 1. Seven different forms of diverse clinical entity have been classified by Sillence and Glorieux, although, recently, up to 11 forms characterized by different genetic mutations have been recognized. Patients with OI suffer from extreme bone fragility and osteoporosis, which often predisposes them to frequent fractures...
August 2016: Medicine (Baltimore)
Alexandra von Au, Eva Milloth, Ingo Diel, Stefan Stefanovic, Andre Hennigs, Markus Wallwiener, Joerg Heil, Michael Golatta, Joachim Rom, Christof Sohn, Andreas Schneeweiss, Florian Schuetz, Christoph Domschke
PURPOSE: Patients with metastasized breast cancer often suffer from discomfort caused by metastatic bone disease. Thus, osteoprotection is an important part of therapy in breast cancer metastasized to bone, and bisphosphonates (BPs) are a major therapeutic option. In this study, our objectives were to compare the side effects of oral versus intravenous BP treatment and to assess their clinical effectiveness. PATIENTS AND METHODS: In this prospective randomized, open-label, non-inferiority trial, we enrolled breast cancer patients with at least one bone metastasis and an Eastern Cooperative Oncology Group performance status of 0-2...
2016: OncoTargets and Therapy
Arianna L Gianakos, Joaquin Moya-Angeler, Shivi Duggal, Lester Zambrana, Kara G Fields, Douglas N Mintz, Charles N Cornell, Joseph M Lane
INTRODUCTION: Osteonecrosis of the femoral head (ONFH) is a devastating disease with complete collapse of the femoral head often reported in greater than 70% of patients within 3 to 4 years of diagnosis. Early intervention prior to collapse may improve the chance of success of joint preserving procedures. QUESTIONS/PURPOSES: The purpose of this study was to evaluate whether core decompression with mesenchymal stem cells combined with bisphosphonate therapy can improve the clinical outcomes and reduce the risk of hip replacement when compared to treatment with bisphosphonate therapy alone...
July 2016: HSS Journal: the Musculoskeletal Journal of Hospital for Special Surgery
Khalid A Azzam, Eric T Rush, Bridget R Burke, Aleisha M Nabower, Paul W Esposito
BACKGROUND: Patients with osteogenesis imperfecta (OI) have significant burden of both fractures and bony deformities. The present approach to care in this disorder is a combination of surgical care with intramedullary rod fixation, cyclic bisphosphonate therapy, and rehabilitation with goal of maximizing patient function and quality of life. METHODS: Retrospective chart review identified 58 children with OI who had realignment osteotomies with Fassier-Duval (FD) intramedullary nailing of the lower extremity by a single surgeon...
July 2, 2016: Journal of Pediatric Orthopedics
Yuki Yamasaki, Takashi Fujimura, Katsunobu Oyama, Yuki Higashi, Atsushi Hirose, Tomoya Tsukada, Koichi Okamoto, Jun Kinoshita, Keishi Nakamura, Tomoharu Miyashita, Hidehiro Tajima, Hiroyuki Takamura, Itasu Ninomiya, Sachio Fushida, Tetsuo Ohta
Proton pump inhibitors (PPIs) are frequently prescribed to patients with gastroesophageal reflux disease; however, the number of bone fractures reportedly increased in these patients. Although PPIs have been shown to inhibit the bone resorption by osteoclasts, the effect of PPIs on skeletal metabolism remains controversial. The aim of the present study was to determine the effect of the PPI rabeprazole on skeletal metabolism using gastrectomized rats. Male Wistar rats were divided into four groups: i) Sham-surgery (n=15); ii) total gastrectomy (TG) control (n=20); iii) TG plus rabeprazole (n=20); and iv) TG plus the bisphosphonate minodronic acid (n=20)...
July 2016: Biomedical Reports
P D Miller, N Pannacciulli, J P Brown, E Czerwinski, B S Nedergaard, M A Bolognese, J Malouf, H G Bone, J-Y Reginster, A Singer, C Wang, R B Wagman, S R Cummings
CONTEXT: Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with osteoporosis. OBJECTIVE: The objective of the study was to compare the effect of transitioning from oral bisphosphonates to denosumab or ZOL on bone mineral density (BMD) and bone turnover. DESIGN AND SETTING: This was an international, multicenter, randomized, double-blind trial. PARTICIPANTS: A total of 643 postmenopausal women with osteoporosis previously treated with oral bisphosphonates participated in the study...
August 2016: Journal of Clinical Endocrinology and Metabolism
Zehui Wu, Zhihao Zha, Seok Rye Choi, Karl Plössl, Lin Zhu, Hank F Kung
INTRODUCTION: In vivo positron emission tomography (PET) imaging of the bone using [(68)Ga]bisphosphonates may be a valuable tool for cancer diagnosis and monitoring therapeutic treatment. We have developed new [(68)Ga]bisphosphonates based on the chelating group, AAZTA (6-[bis(hydroxycarbonyl-methyl)amino]-1,4-bis(hydroxycarbonyl methyl)-6-methylperhydro-1,4-diazepine). METHOD: Phenoxy derivative of AAZTA (2,2'-(6-(bis(carboxymethyl)amino)-6-((4-(2-carboxyethyl)phenoxy)methyl)-1,4-diazepane-1,4-diyl)diacetic acid), PhenA, 2, containing a bisphosphonate group (PhenA-BPAMD, 3, and PhenA-HBP, 4) was prepared...
June 2016: Nuclear Medicine and Biology
Mürüde Yazan, Fethi Atil, Ismail Doruk Kocyigit, Umut Tekin, Hakan Hifzi Tuz, Melda Misirlioglu
BACKGROUND: Bisphosphonates are used throughout supportive cancer therapies for the treatment of osteoporosis and metastatic bone diseases, but they invariably induce medication-related osteonecrosis of the jaw (MRONJ). This medicational modality may induce consequential losses that can lead to spontaneous or surgical therapy related bone fractures or defects. MRONJ stages and treatment alternatives are described in the current procedures. Accordingly, treatments for stages 0 and 1 are conservative whereas the treatment for stage 3 is surgical resection of the necrotic bone...
June 2016: Journal of Craniofacial Surgery
Chanchal Kumar, Inusha Panigrahi, Abhishek Somasekhara Aradhya, Babu Lal Meena, Niranjan Khandelwal
BACKGROUND: The advent of bisphosphonates (BPs) has revolutionised the outcome of Osteogenesis imperfecta (OI) in the last few years. There has always been a safety concern regarding zoledronate's use due to a paucity of studies. The current study is a retrospective evaluation of children with OI on the short- and long-term side effects of zoledronate and the frequency of fractures per year after the drug was introduced. METHODS: A total of 26 children diagnosed with OI, with a median age of 84 (45-121) months were enrolled in the study...
August 1, 2016: Journal of Pediatric Endocrinology & Metabolism: JPEM
Yuko Komatsu, Miho Ibi, Naoyuki Chosa, Seiko Kyakumoto, Masaharu Kamo, Toshiyuki Shibata, Yoshiki Sugiyama, Akira Ishisaki
Bisphosphonates (BPs) are analogues of pyrophosphate that are known to prevent bone resorption by inhibiting osteoclast activity. Nitrogen-containing BPs, such as zoledronic acid (ZA), are widely used in the treatment of osteoporosis and bone metastasis. However, despite having benefits, ZA has been reported to induce BP-related osteonecrosis of the jaw (BRONJ) in cancer patients. The molecular pathological mechanisms responsible for the development of BRONJ, including necrotic bone exposure after tooth extraction, remain to be elucidated...
July 2016: International Journal of Molecular Medicine
Robert M Conry, Michael G Rodriguez, Joseph G Pressey
BACKGROUND: Zoledronic acid (ZA) is a third-generation bisphosphonate in widespread clinical use to reduce pain and skeletal events in patients from a variety of malignancies with bone metastases. Pre-clinical studies indicate that ZA inhibits osteosarcoma through direct anti-proliferative effects, immune activation and anti-angiogenic activity. METHODS: The purpose of this study was to evaluate the antitumor efficacy of ZA at standard dose until progression in patients with stage IV osteosarcoma lacking a standard of care treatment option proven to influence survival...
2016: Clinical Sarcoma Research
Carolina Borges, Silvia Spivakovsky
DATA SOURCES: PubMed Medline, Embase, LILACS, and reference lists of potential eligible studies. STUDY SELECTION: Prospective control trials, cohort and case series analysing results on at least 20 patients treated with ARD therapy (IV or orally). Studies reporting a protocol used for dental extraction in patients on ARD; studies reporting data on medically related osteonecrosis of the jaw after dental extraction. DATA EXTRACTION AND SYNTHESIS: Two review authors independently assessed titles and abstracts for each article identified by the searches in order to decide whether the article was likely to be relevant...
March 2016: Evidence-based Dentistry
Oliver Sartor, Peter Hoskin, Robert E Coleman, Sten Nilsson, Nicholas J Vogelzang, Oana Petrenciuc, Karin Staudacher, Marcus Thuresson, Christopher Parker
BACKGROUND: Radium-223 prolongs overall survival in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases, regardless of prior docetaxel. Whether or not chemotherapy can be safely administered following radium-223 treatment is of clinical importance. An exploratory analysis of prospectively collected data, from the ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) patient subgroup who received chemotherapy after radium-223 or placebo treatment, was conducted to evaluate the safety and efficacy of chemotherapy following radium-223...
July 2016: Prostate
John-David Black, Vamsi K Kancherla, William G De Long
OBJECTIVE: To evaluate the experience of a single tertiary care teaching hospital with the association between use of bisphosphonates and atypical femoral fractures, and to identify potential risk factors and chronologic incidence. DESIGN: Retrospective review. SETTING: Tertiary-care teaching hospital. PATIENTS: Thirty-two patients with a total of 43 fractures met inclusion criteria. INTERVENTION: Treatment for atypical femur fractures...
April 2016: Journal of Orthopaedic Trauma
K Lindahl, A Kindmark, C-J Rubin, B Malmgren, G Grigelioniene, S Söderhäll, Ö Ljunggren, E Åström
BACKGROUND: Osteogenesis imperfecta (OI) is an inherited heterogeneous bone fragility disorder, usually caused by collagen I mutations. It is well established that bisphosphonate treatment increases lumbar spine (LS) bone mineral density (BMD), as well as improves vertebral geometry in severe OI; however, fracture reduction has been difficult to prove, pharmacogenetic studies are scarce, and it is not known at which age, or severity of disease, treatment should be initiated. MATERIALS AND METHODS: COL1A1 and COL1A2 were analyzed in 79 children with OI (type I n=33, type III n=25 and type IV n=21) treated with Pamidronate...
June 2016: Bone
Atsuko Sato, Jean Ouellet, Takeshi Muneta, Francis H Glorieux, Frank Rauch
Bisphosphonates are widely used to treat children with osteogenesis imperfecta (OI), a bone fragility disorder that is most often caused by mutations in COL1A1 or COL1A2. However, it is unclear whether this treatment decreases the risk of developing scoliosis. We retrospectively evaluated spine radiographs and charts of 437 patients (227 female) with OI caused by mutations in COL1A1 or COL1A2 and compared the relationship between scoliosis, genotype and bisphosphonate treatment history. At the last follow-up (mean age 11...
May 2016: Bone
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"